School of Pharmacy, Lebanese International University, Beirut, Lebanon.
Department of Obstetrics and Gynecology, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Br J Clin Pharmacol. 2018 May;84(5):1077-1080. doi: 10.1111/bcp.13560. Epub 2018 Mar 9.
A 30-year-old pregnant female presented with a 2-week history of pityriasis rosea-like eruption. The rash started 2 days after the patient had started taking ondansetron 8 mg for alleviation of moderate-to-severe nausea and vomiting of pregnancy. Physical examination revealed erythematous papulosquamous lesions characterized by annular scaly margins and a dusky centre over the arms, chest, abdomen, lower back and legs. The rash did not involve the palms, sole or mucous membranes, and no lesions were observed on the lymph nodes. Ondansetron was discontinued. The rash ceased to spread and started to disappear within 2 weeks with full resolution noted after 1 month. Analysis of the case using the Naranjo adverse drug reaction probability scale indicated that ondansetron was the probable cause of the pityriasis rosea-like eruption. This is the first case report of pityriasis rosea related to ondansetron therapy.
一位 30 岁的孕妇出现了为期两周的玫瑰糠疹样疹。皮疹在患者开始服用昂丹司琼 8mg 缓解妊娠中重度恶心和呕吐后 2 天开始出现。体格检查显示手臂、胸部、腹部、下背部和腿部有红斑鳞屑性病变,边界呈环状鳞屑,中央呈暗褐色。皮疹不累及手掌、足底或粘膜,淋巴结无病变。停用昂丹司琼后,皮疹停止扩散并在 2 周内开始消失,1 个月后完全消退。使用 Naranjo 药物不良反应概率量表对该病例进行分析,表明昂丹司琼是引起玫瑰糠疹样疹的可能原因。这是首例与昂丹司琼治疗相关的玫瑰糠疹病例报告。